News

insert an image 968px x 220px

News

Gentronix Announces Addition to its Executive Team and Board of Directors

Posted on November 12, 2007 by Studio North

Gentronix Ltd, leaders in cellular biosensor systems for pre-clinical genetic toxicology announced today the appointment of Dr Steven Beasley as Commercial Director and member of the board. Steve joins Gentronix with over twenty years experience of the pharmaceutical and biotechnology industry gained from both research and commercial roles. Previously CEO of bioscience knowledge organization bioKneX and Chief Business Officer of De Novo Pharmaceuticals Ltd, Steve will head the commercial operations of Gentronix as it moves forward with its growth plans for GreenScreen HC and its next generation products. John Nicholson, Chairman and CEO of Gentronix said, “The team and I…

Read the rest of this news item

GreenScreen HC presented to European Partnership for Alternative Approaches to Animal Testing

Posted on November 1, 2007 by Studio North

Prize winning work by GlaxoSmithKline and Gentronix Ltd in improving the identification of cancer causing chemicals using GreenScreen HC was presented to parliamentarians at the annual meeting of the European Commission Partnership on Alternatives to Animal Testing (EPAA). The cell-based genotoxicity screening assay from Gentronix, GreenScreen HC, is much more accurate for these specific tests than the existing cell culture assays, thus far fewer chemicals have then to be tested in animals; tests which are currently necessary to see whether chemicals actually have the potential to cause cancer. The work was presented at the EPAA annual meeting in Brussels in…

Read the rest of this news item

BioReliance Launches Next-Generation Genotoxicity Screening Service

Posted on September 12, 2007 by Studio North

BioReliance Corporation, a leading contract services organization for the biopharmaceutical and pharmaceutical industries, has contracted with Gentronix to offer their GreenScreen HC in vitro assay as a major part of BioReliance’s portfolio of genotoxicity screening services. GreenScreen HC, in conjunction with Ames II assays, allows pharmaceutical companies to test for genotoxic potential earlier in the preclinical development process, using only a few milligrams of test compound as opposed to the gram quantities required by current ICH regulatory tests. Click here to download service flyer. read more …

Read the rest of this news item

NVM Invests £1 million in Gentronix

Posted on March 3, 2007 by Studio North

NVM invests in Pioneering Drug Safety Testing Company. NVM Private Equity Limited (NVM) has committed £1 million as part of a new funding round of £1.4 million into Gentronix. The pioneering Manchester based company has developed a novel process enabling the pharmaceutical industry to test new drugs for potential carcinogenicity. Gentronix’s GreenScreen HC process tests new drugs for potentially cancerous toxins at a very early stage. This saves huge expenditure developing drugs that ultimately fail genotoxicity trials. Globally the pharmaceutical sector spends an estimated $53 billion a year on research and development; despite this an average of less than 26…

Read the rest of this news item